AbbVie lifts profit target after cancer drug powers quarterly beat

AbbVie Inc beat Wall Street estimates for third-quarter profit on Friday, driven by strong sales of blockbuster cancer medicine Imbruvica, and the drugmaker raised its 2018 earnings forecast, sending its shares up 4 percent.